---
title: Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
nct_id: NCT01647334
overall_status: TERMINATED
phase: NA
sponsor: "London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's"
study_type: INTERVENTIONAL
primary_condition: Non Small Cell Lung Cancer
countries: Canada
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01647334.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01647334"
ct_last_update_post_date: 2015-02-19
last_seen_at: "2026-05-12T07:23:05.884Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer

**NCT ID:** [NCT01647334](https://clinicaltrials.gov/study/NCT01647334)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** Poor accrual
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 29
- **Lead Sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Collaborators:** London Regional Cancer Program, Canada
- **Conditions:** Non Small Cell Lung Cancer
- **Start Date:** 2013-01
- **Completion Date:** 2014-12
- **CT.gov Last Update:** 2015-02-19

## Brief Summary

This study aims to use a type of radiation (adaptive radiotherapy) to deliver curative-intent treatment to patients with non-small cell lung cancer, whose tumors would otherwise be too large for standard curative treatment. The study will use adaptive radiotherapy to achieve these goals. Adaptive radiotherapy is a process whereby treatment plans are modified during the course of treatment due to patient and tumor variations (ie. weight loss or tumor shrinkage). This may allow for dose escalation, while limiting the side effects.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age 18 or older
* Willing to provide informed consent
* ECOG performance status 0-2
* Histologically confirmed non-small cell lung carcinoma
* Locally advanced stage IIIA or IIIB lung carcinoma according to AJCC 7th edition
* Expected lung V20 of 35-60%, as determined at the time of 4D-CT simulation
* Assessment by medical oncologist and radiation oncologist, with adequate hepatic and renal function for administration of cisplatin-based doublet chemotherapy, at the discretion of the medical oncologist

Exclusion Criteria:

* Serious medical comorbidities or other contraindications to radiotherapy or chemotherapy
* Prior history of lung cancer within 5 years
* Prior thoracic radiation at any time
* Metastatic disease
* in some select cases, patients with a solitary metastasis (i.e. brain metastasis) may receive radical chemoradiotherapy after resection/ablation of their metastatic lesion, as standard practice. In such cases, the patient may be enrolled onto this study at the discretion of the local principle investigator once the metastasis has been treated.
* inability to attend full course of radiotherapy of follow-up visits
* Pregnant or lactating women
```

## Arms

- **Shrinking Target Adaptive Radiotherapy** (EXPERIMENTAL) — Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer

## Interventions

- **Adaptive radiotherapy** (RADIATION)

## Primary Outcomes

- **Tumor reduction** _(time frame: 2.5 years (end of treatment))_

## Secondary Outcomes

- **Rate of tumor shrinkage** _(time frame: 2.5 years (end of treatment))_
- **Change in lung dose** _(time frame: 2.5 years (end of treatment))_
- **Delivered doses** _(time frame: 2.5 years (end of treatment))_
- **Radiation pneumonitis rates** _(time frame: 6 months, 12 months, 18 months, 24 months, 30 months (semi-annually))_
- **Local control** _(time frame: 2.5 years (end of treatment))_
- **Overall survival** _(time frame: 2.5 years)_

## Locations (1)

- London Regional Cancer Program of the Lawson Health Research Institute, London, Ontario, Canada

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.london regional cancer program of the lawson health research institute|london|ontario|canada` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01647334.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01647334*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*